Paper · 40933191
Plasma FGF2 and YAP1 as novel biomarkers for MCI in the elderly: analysis via bioinformatics and clinical study.
Zhao Y and 7 others. Front Neurosci, 2025. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Plasma FGF2 and YAP1 as novel biomarkers for MCI in the elderly: analysis via bioinformatics and clinical study. Papers, record 40933191. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40933191
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Plasma FGF2 and YAP1 as novel biomarkers for MCI in the elderly: analysis via bioinformatics and clinical study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,270,743 | Consequences of Metabolic Disruption in Alzheimer's Disease Pathology. | Neurotherapeutics | 2019 | https://conductscience.org/library/papers/31270743 | PubMed |
| 2 | 31,980,612 | YAP-dependent necrosis occurs in early stages of Alzheimer's disease and regulates mouse model pathology. | Nat Commun | 2020 | https://conductscience.org/library/papers/31980612 | PubMed |
| 3 | 25,201,954 | Substratum-induced differentiation of human pluripotent stem cells reveals the coactivator YAP is a potent regulator of neuronal specification. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/25201954 | PubMed |
| 4 | 27,381,227 | YAP stabilizes SMAD1 and promotes BMP2-induced neocortical astrocytic differentiation. | Development | 2016 | https://conductscience.org/library/papers/27381227 | PubMed |
| 5 | 37,879,209 | Sarsasapogenin inhibits YAP1-dependent chondrocyte ferroptosis to alleviate osteoarthritis. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37879209 | PubMed |
| 6 | 35,979,359 | YAP1 alleviates sepsis-induced acute lung injury via inhibiting ferritinophagy-mediated ferroptosis. | Front Immunol | 2022 | https://conductscience.org/library/papers/35979359 | PubMed |
| 7 | 32,333,900 | Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. | Lancet Neurol | 2020 | https://conductscience.org/library/papers/32333900 | PubMed |
| 8 | 32,347,652 | MiR-646 suppresses proliferation and metastasis of non-small cell lung cancer by repressing FGF2 and CCND2. | Cancer Med | 2020 | https://conductscience.org/library/papers/32347652 | PubMed |
| 9 | 30,938,796 | Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. | JAMA | 2019 | https://conductscience.org/library/papers/30938796 | PubMed |
| 10 | 33,585,983 | Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. | Acta Neuropathol | 2021 | https://conductscience.org/library/papers/33585983 | PubMed |
1 to 10 of 45
See all 45 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,690,514 | Fibroblast growth factors in Alzheimer's Disease pathogenesis: neuropharmacological implications for neuroprotection, neurogenesis, and therapeutic development. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42690514 | PubMed |
| 42,682,425 | Increased serum fibroblast growth factor 2 levels, altered peripheral blood inflammatory indicators and their ratios in amyotrophic lateral sclerosis: a clinical exploratory study. | Front Neurol | 2026 | https://conductscience.org/library/papers/42682425 | PubMed |
| 41,306,424 | Expression of dementia biomarkers in Appalachian and non-Appalachian ELVO patients during thrombectomy. | Front Neurosci | 2025 | https://conductscience.org/library/papers/41306424 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FGF2 | 2,247 | PubTator's text mining | https://conductscience.org/library/genes/2247 | NCBI Gene |
| YAP1 | 10,413 | PubTator's text mining | https://conductscience.org/library/genes/10413 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40933191
GET https://conductscience.org/api/papers/v1/40933191/references?page=2